Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary AMARIN ANNOUNCES CHANGES TO ITS BOARD AND MANAGEMENT TEAM
AMARIN ANNOUNCES CHANGES TO ITS BOARD AND MANAGEMENT TEAM AMARIN ANNOUNCES CHANGES TO ITS BOARD AND MANAGEMENT TEAM DUBLIN, Ireland, October 13, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced changes to its board and management team, in conjunction with its separately announced $70
View HTML
Toggle Summary AMARIN RECEIVES EXTENSION FROM NASDAQ TO FILE ITS 2008 ANNUAL REPORT ON FORM 20-F
AMARIN RECEIVES EXTENSION FROM NASDAQ TO FILE ITS 2008 ANNUAL REPORT ON FORM 20-F DUBLIN, Ireland, October 5, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that Nasdaq has granted the Company’s requested extension to the deadline to file its 2008 Annual Report on Form 20-F with the
View HTML
Toggle Summary AMARIN ANNOUNCES EXTENSION TO BRIDGE FINANCING
AMARIN ANNOUNCES EXTENSION TO BRIDGE FINANCING DUBLIN, Ireland, October 1, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that it has reached an agreement with the lenders of the Company’s $5.5 million bridge financing to extend the maturity date to October 16, 2009.
View HTML
Toggle Summary AMARIN ANNOUNCES $3.0 MILLION BRIDGE FINANCING
AMARIN ANNOUNCES $3.0 MILLION BRIDGE FINANCING DUBLIN, Ireland, August 3, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that it has executed an agreement for the private placement of convertible bridge loan notes (“Bridge Financing”) in the amount of $3.0 million with select
View HTML
Toggle Summary Amarin Receives Special Protocol Assessment Agreement From The FDA For Phase 3 Trial In Mixed Dyslipidemia
Amarin Receives Special Protocol Assessment Agreement From The FDA For Phase 3 Trial In Mixed Dyslipidemia DUBLIN, Ireland, July 9, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol
View HTML
Toggle Summary Amarin Announces Signing Of Non-Binding Term Sheet For Private Placement Of Up To $55 Million
Amarin Announces Signing Of Non-Binding Term Sheet For Private Placement Of Up To $55 Million Amarin Announces Signing Of Non-Binding Term Sheet For Private Placement Of Up To $55 Million DUBLIN, Ireland, July 7, 2009 – Amarin Corporation plc (NASDAQ: AMRN) announced today that that it has entered
View HTML
Toggle Summary Amarin Receives NASDAQ Notification Related To Late Filing Of 2008 Annual Report On Form 20-F
Amarin Receives NASDAQ Notification Related To Late Filing Of 2008 Annual Report On Form 20-F DUBLIN, Ireland, July 7, 2009 – Amarin Corporation plc (NASDAQ: AMRN) announced today that on July 6, 2009, the Company received a written notification from the Nasdaq Stock Market stating that it is not
View HTML
Toggle Summary Amarin Reports Preliminary Unaudited Financial Results For The Six And Twelve Months Ended December 31, 2008
Amends Terms to Extend Bridge Financing Reports Delay in Filing 2008 Annual Report
View HTML
Toggle Summary Amarin Reports Preliminary Unaudited Financial Results For The Six And Twelve Months Ended December 31, 2008
Amends Terms to Extend Bridge Financing Reports Delay in Filing 2008 Annual Report
View HTML
Toggle Summary Amarin Announces Revision To Non-Binding Term Sheet For Private Placement Of Up To $55 Million
Amarin Announces Revision To Non-Binding Term Sheet For Private Placement Of Up To $55 Million DUBLIN, Ireland, July 22, 2009 – Amarin Corporation plc (NASDAQ: AMRN) announced today that it has revised the terms of the previously announced non-binding term sheet relating to the private placement of
View HTML
copyright
© 2018, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
2 Pembroke House, Upper Pembroke
Street 28-32
Dublin 2, Ireland
US Investor Relations
Amarin Pharma Inc.
1430 Route 206
Bedminster, NJ 07921 USA
Telephone:
+1 908 719 1315
Fax:
+1 908 719 3012

Amarin Corporation